Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: Code of Conduct Sets European Medtech Industry On The Front Foot

This article was originally published in Clinica

Executive Summary

European medical device and diagnostics manufacturers have adopted a new common Code of Ethical Business Practice which will be implemented nationally as of 2017. Industry sees the code as part of efforts to set visibly high ethical standards and as a clear signal to other stakeholders of how seriously it takes stringent self-regulation. Clinica asked UK ABHI chairman Phil Kennedy what he hopes the initiative will achieve

You may also be interested in...

IVD UK Spring Meeting: Diagnostics Get New Market Access Tools – But At A Price

First of two articles covering discussion at the spring 2017 meeting of the British In Vitro Diagnostics Association: The UK IVD companies are soon to get new tools designed to make market access for innovations easier and more predictable. This is welcome news, given the backdrop of Brexit and the costly route to compliance to the new EU IVD Regulation compliance.

Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s

Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.

When Will POC Really Be On The Cusp Of Major Uptake?

Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts